CLINICAL AND THERAPEUTIC STUDIES IN HUMAN FILARIASIS

伊维菌素在印度南部和其他地方的试验中显示， 在清除班氏病人的微丝蚴血症方面非常有效 丝虫病 目前在南印度和巴西进行的研究（与 在世界其他地方的试验）都集中在制定一个方案， 优化微丝蚴清除的持续时间。 最近的研究表明，热带肺嗜酸性粒细胞增多症 类圆线虫病和丝虫病均可引起该综合征。 工作要 区分这两种肺嗜酸性粒细胞性疾病， 正在进行适当的治疗。 在流行地区逗留的外籍游客的特点是， 对丝虫有明显的临床和免疫高反应性， 寄生虫 低反应性的假设状态，包括临床和 免疫学上，在流行地区的感染者中， 在西非贝宁的研究已经证明了这一点。 治疗 阿苯达唑亦正在当地进行试验。

Ivermectin has been shown in trials in both South India and elsewhere to be very effective in clearing microfilaremia in patients with bancroftian filariasis. Current studies in South India and Brazil (coordinated with trail elsewhere in the world) are focussed on developing a regimen to optimize the duration of microfilarial clearance. Recent investigation has indicated that the Tropical Pulmonary Eosinophilia syndrome can be caused by strongyloides as well as by filariae. Work to differentiate these two pulmonary eosinophilic conditions and develop appropriate therapy is underway. Loiasis in expatriate visitors to endemic areas has been characterized as having marked clinical and immunologic hyperresponsiveness to the filarial parasite. The hypothesized state of hyporesponsiveness, both clinical and immunological, in infected individuals native to the endemic regions has now been demonstrated by studies in Benin, West Africa. A therapeutic trial of albendazole for loiasis is also underway there.